On Tuesday, Oragenics Inc. (NYSE:OGEN) said it has completed a key study for its new concussion drug, ONP-002. What Happened: A recent study shows that the drug successfully targets areas inside the nose connected to the brain, making the drug more likely to reach and treat the brain after a concussion. In the study, ONP-002 was tested using a nasal spray device. The goal of intranasal casting studies is to identify where the drug lands inside a cast metal anatomical model of the interior nose. The model is standard for intranasal drug delivery and is accepted by the FDA as a surrogate for the…